Zhengda Tianqing’s bispecific ADC is approved for clinical trials, and the competition for EGFR/c-Met targets heats up again

June 23, 2025  Source: drugdu 80

Recently, the official website of the Center for Drug Evaluation (CDE) of the China National Drug Administration showed that the TQB6411 injection, a Class 1 innovative drug independently developed by Zhengda Tianqing, has been approved for clinical use and is intended to be used to treat patients with advanced malignant tumors. As a dual-antibody ADC (antibody-drug conjugate) targeting EGFR/c-Met, this drug has become a "new species" that has not yet been approved for marketing in the world.

The design logic of TQB6411 directly targets the key pain points of tumor treatment - drug resistance and compensatory activation of signal pathways. Epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (c-Met) are driver genes for various tumors such as lung cancer and colorectal cancer, and often form synergistic effects in signal transduction.

When a drug inhibits only one of the pathways, the other pathway may be compensatorily activated, resulting in treatment failure. The simultaneous blockade of dual targets can simultaneously inhibit the PI3K/AKT/mTOR and Ras/Raf/Mek dual pathways, strangling the escape path of tumor cells from the source.

The drug accurately locks the EGFR and c-Met proteins on the surface of tumor cells through its dual-antibody structure, blocking downstream signal activation; at the same time, it releases cytotoxins with the help of enzyme-cleavable linkers to directly induce tumor cell apoptosis.

Preclinical studies have shown that even in single-target resistant models of EGFR or c-Met, TQB6411 still exhibits significant anti-tumor activity, suggesting that it has the potential to overcome drug resistance.

"/
It is understood that the drug has completed systematic pharmacology, pharmacokinetics and safety verification. In animal models, it showed anti-tumor activity against different EGFR/c-Met expression levels and drug resistance types, suggesting that it has broad-spectrum therapeutic potential.

The approval of TQB6411 not only adds another product to Zhengda Tianqing's ADC research and development pipeline, but also marks that Chinese local pharmaceutical companies have taken substantial steps in the cutting-edge field of bispecific ADC.

https://news.yaozh.com/archive/45658.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.